Recent Posts
- Press release: Adoram Therapeutics Secures CHF 1 Million Grant from Innosuisse for Anti-inflammatory Drug Research
- Adoram primary asset published in the Journal of Medicinal Chemistry, January 24th 2025
- Press release: Adoram Therapeutics Secures Pre-Seed Investment to Advance Innovative Cancer Immunotherapy and Inflammation Programs
- Adoram Therapeutics receives funding from FONGIT Innovation Fund
- South Summit International Startup Competition. June 5-7th, 2024
Recent Comments
No comments to show.